Isolation and identification of two galangin metabolites from rat urine and determination of their in vitro hypolipidemic activity

Xuguang Zhang1,2, Shouqian Cheng1,2, Hailong Li1,2, Xiaopo Zhang2, Feng Chen1,2, Youbin Li1,2, Junqing Zhang1,2* and Yinfeng Tan1,2

1Hainan Provincial Key Laboratory of R&D of Tropical Herbs, 2School of Pharmaceutical Science, Hainan Medical University, Haikou, 571101, PR China

*For correspondence: Email: jzhang2011@163.com, secondmessenger@163.com; Tel: +86 898 66895337; Fax: +86 898 66895337

Received: 24 November 2015 Revised accepted: 14 May 2016

Abstract

Purpose: To investigate the lipid-lowering activity of two metabolites of galangin, namely, galangin-3-O-β-D-glucuronic acid (GG-1) and galangin-7-O-β-D-glucuronic acid (GG-2).

Methods: Female Sprague-Dawley rats were orally administered with galangin. The two metabolites of galangin were isolated from urine sample and purified using Sephadex LH-20 and semi-preparative high performance liquid chromatography (HPLC). The structures of the metabolites were identified by analyzing spectroscopic data. Hypolipidemic activity was evaluated in HepG2 cells. The down- or up-regulation of lipogenic genes was detected using real-time quantitative polymerase chain reaction (qPCR).

Results: Both metabolites of galangin showed hypolipidemic activity. These activities are closely associated with the down-regulation of lipogenic genes such as SREBP-1a, SREBP-1c, and SREBP-2 transcription factors, and the downstream genes such as FAS, ACC, and HMGR were revealed by real-time qPCR data.

Conclusion: The results show that both metabolites possess better lipid-lowering activities than galangin. These hypolipidemic activities are closely associated with inhibiting key genes or proteins that regulated the biosynthesis of both cholesterol and triglycerides.

Keywords: Galangin, Galangin-3-O-β-D-glucuronic acid, Galangin-7-O-β-D-glucuronic acid, Hypolipidemic, Lipogenic genes, Metabolites

INTRODUCTION

Obesity is becoming a serious threat to human beings [1]. More accumulation of lipids in liver is a key cause for insulin resistance [2]. Therefore, decreasing lipid deposition in liver through inhibition of lipogenesis or stimulation of lipolysis is an effective way for the prevention and treatment of obesity and diabetes [3-4]. Natural products such as cordycepin [5], resveratrol [6], and berberine [7] have showed ability in suppressing lipogenesis and accumulation of fat, and are considered to be the potential candidates in developing new therapeutic agents.

Galangin, a natural flavonoid obtained from Alpinia officinarum, has been found to possess various biological activities [8,9]. Specifically, this compound showed a significant decrease in
serum lipids, liver weight, peroxidation of lipids, and accumulation of hepatic triglycerides, which suggested that galangin has the potential for controlling obesity [10]. Interestingly, previous pharmacokinetic studies have found two metabolites of galangin, and are considered as the effective in vivo components [11-12]. However, the limitations in developing new therapeutic agent from galangin are mainly due to its low bioavailability. Therefore, the metabolites obtained from urine samples may be considered as the better candidates. From this approach, two metabolites namely galangin-3-O-β-D-glucuronic acid (GG-1) and galangin-7-O-β-D-glucuronic acid (GG-2) were obtained from the rat urine. In addition, the effects of these two metabolites on lipid accumulation in HepG2 cells and its hypolipidemic mechanisms were investigated to find potential utility in the prevention and treatment of obesity.

**EXPERIMENTAL**

**General experimental procedures**

HepG2 cells were obtained from the American Type Culture Collection (Manassas, Virginia, USA) and China Union Medical University. 1H, 13C-nuclear magnetic resonance (NMR) experiments were performed on Bruker spectrometer operating at 400 MHz for 1H and 100 MHz for 13C (tetramethylsilane was used as an internal standard). Chemical shifts were expressed in ppm referenced to solvent peaks at δH 2.50 and δC 39.6 in dimethyl sulfoxide (DMSO)-d6, and coupling constants were in Hz. Electrospray ionization-mass spectrometry (ESI-MS) was obtained from a Thermo Scientific LTQ-Orbitrap XL instrument (Bremen, Germany). Sephadex LH-20 (GE Health care) was used for column chromatography. High performance liquid chromatography (HPLC) was performed on LC-20A (Shimadzu), and a column of Zorbax SB-phenyl (250 × 9.4mm, 5 μm, Agilent Technologies Co., Ltd.). Mixtures of methanol (CH3OH)/water (H2O) were used as an eluent. All solvents used were of analytical grade.

**Reagents**

Galangin was extracted from Alpinia officinarum in laboratory previously. The chemical structure of galangin was established by analyzing NMR data and compared with literature. The purity of galangin (> 95 %) was determined using HPLC equipped with a UV detector with an Agilent eclipse XDB-C18 column (5μm, 4.6×250 mm). Then, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was obtained from Sigma-Aldrich (Saint Louis, Missouri, USA).

**Animals**

All animal experiments were performed per International Guidelines for Care and Use of Laboratory Animals [20] and approved by the animal ethics committee of Hainan Medical University (reg. no. 201506017/HMU). Female Sprague-Dawley rats (240 to 300 g) were purchased from DongChuang Laboratory Animal Service Department (Changsha, China). Commercial rat chow was available ad libitum except for an overnight fasting period before dosing. All rats were provided with free access to H2O.

**Urine collection**

Rats were housed separately in rat metabolic cages. Urine samples were collected before and after 0-24 h oral dose of galangin (90 mg/kg). For the oral administration, 30 mg/mL of galangin solution was dissolved in distilled H2O containing 2 % (w/v) tween-80.

**Extraction and isolation of two galangin metabolites**

The collected urine samples were pooled. Then, 300 mL of pooled urine samples was diluted with 700 mL of distilled H2O to give 1000 mL of solvent. Then, the solvent was partitioned twice with 300 mL of ethyl acetate and n-butanol to give two extracts, respectively. These extracts were concentrated successively under reduced pressure to obtain the ethyl acetate (2.0 g) and n-butanol (5.0 g). The n-butanol extract was separated with Sephadex LH-20 using CH3OH as an eluent to yield six fractions (Fr.1 to Fr.6). Fr.5 (800 mg) was further purified by semi-preparative HPLC with CH3OH:H2O (40:60) as an eluent to give compounds 1 (6.0 mg), and 2 (8.0 mg).

**Cell-based lipid accumulation assay**

HepG2 cells were maintained in a Dulbecco’s modified eagles medium (DMEM, Gibco, Grand Island, New York, USA) supplemented with 10 % fetal bovine serum (Gibco) and 100 μg/mL of penicillin/streptomycin (Gibco). After reaching 70-80 % confluence, the cells were incubated in DMEM and 100 μM of oleic acid (OA, Sigma-Aldrich, Shanghai, China) for 12 h, then the cells were treated with 10 μM of indicated compounds or marketed antihyperlipidemic drug simvastatin (Sigma-Aldrich) in DMEM and 100 μM of OA or with DMEM and 100 μM of OA alone for another 24 h.
6 h. Subsequently, the cells were subjected to oil-red O staining, total cholesterol and triglycerides were determined as described previously [19]. Each experiment was repeated for three times.

MTT assay

HepG2 cells were cultured in a 24-well plate. After reaching confluence, the cells were incubated for 48 h in presence of GG-1, GG-2, and galangin. Subsequently, the culture medium was removed and replaced with 500 μL of fresh culture medium containing 10 % sterile filtered MTT. After 3 h, the formed insoluble formazan crystals were dissolved in 500 μL of isopropanol per well and absorbance was measured at 570 nm using the 630 nm reading as a reference. The inhibition of growth due to tested compounds was expressed as a percentage of viable cells in experimental wells than in control wells.

Real-time quantitative polymerase chain reaction (qPCR)

The mRNA levels of lipid metabolism-related genes were determined using real-time qPCR. Total RNA extraction, cDNA synthesis, and quantitative PCR assays were all performed as described previously [20]. Samples were cycled 40 times using a fast applied biosystems (ABI)-7500 sequence detector (Foster City, USA). ABI-7500 cycle conditions were as follows: denaturation at 95 °C for 5 min followed by 40 cycles at 95 °C for 15 s, annealing at 60 °C for 30 s, and holding at 72 °C for 30 s. Cycle threshold was calculated under default settings of real-time sequence detection software (Applied Biosystems). Three independent biological replicates were analyzed to check the reproducibility of the data.

Statistical analysis

Data are presented as mean ± standard deviation. One-way analysis of variance was used to determine the significant difference between both groups. Modified Student’s t-test with the Bonferroni correction was used to compare the difference between individual groups. P < 0.05 was considered as statistically significant.

RESULTS

Spectral data for GG-1, GG-2, and galangin

**GG-2**: ESI-MS m/z 444.9 [M-H]; 1H-NMR (400 MHz, DMSO-d$_6$) δ: 12.38 (1H, br.s, 5-OH), 8.10 (2H, d, J=7.5 Hz, H-2', 6'), 7.52 (3H, m, H-3', 4', 5'), 6.85 (1H, br.s, H-8), 6.44 (1H, br.s, H-6'), and 5.13 (1H, d, J=7.2 Hz, H-1'); and 13C-NMR (100 MHz, DMSO-d$_6$) δ: 178.1 (C-4), 172.2 (C-6'), 163.0 (C-7), 162.6 (C-5), 157.0 (C-9), 156.3 (C-2), 134.5 (C-3), 131.1 (C-1'), 130.9 (C-4'), 129.6 (C-2', 6'), 128.6 (C-3', 5'), 104.3 (C-10), 99.2 (C-6), 94.3 (C-8), 76.7 (C-3'), 74.8 (C-5'), 74.3 (C-2'), and 72.5 (C-4').

**Galangin**: ESI-MS m/z 268.9 [M-H]; 1H-NMR (400 MHz, DMSO-d$_6$) δ: 12.36 (1H, br.s, 5-OH), 8.14 (2H, m, J=7.5 Hz, H-4'), 7.50-7.55 (3H, m, H-3', 4', 5'), 6.45 (1H, br.s, H-8), and 6.20 (1H, br.s, H-6); and 13C-NMR (100 MHz, DMSO-d$_6$) δ: 176.3 (C-4), 164.3 (C-7), 160.8 (C-5), 156.5 (C-9), 145.8 (C-2), 131.2 (C-3), 131.4 (C-1'), 130.6 (C-4'), 129.0 (C-2', 6'), 128.1 (C-3', 5'), 105.3 (C-10), 99.4 (C-6), 94.8 (C-8), 76.7 (C-3'), 74.7 (C-5'), 73.3 (C-2'), and 72.3 (C-4').

**Characteristic features of the two galangin metabolites**

Compound 1 was obtained as a brown powder. The spectral data of 1H-NMR were resonated at δ: 12.38 (1H, br.s, 5-OH), 8.13 (2H, d, J=7.5 Hz, H-2', 6'), 7.52 (3H, m, H-3', 4', 5'), 6.26 (1H, br.s, H-8), 6.08 (1H, br.s, H-6), and 5.54 (1H, d, J=7.2 Hz, H-1'); and 13C-NMR (100 MHz, DMSO-d$_6$) δ: 178.1 (C-4), 172.2 (C-6'), 163.0 (C-7), 162.6 (C-5), 157.0 (C-9), 156.3 (C-2), 134.5 (C-3), 131.1 (C-1'), 130.9 (C-4'), 129.6 (C-2', 6'), 128.6 (C-3', 5'), 104.3 (C-10), 99.2 (C-6), 94.3 (C-8), 76.7 (C-3'), 74.8 (C-5'), 74.3 (C-2'), and 72.5 (C-4').

Compound 2 was also obtained as a brown powder. The spectral data of NMR and MS were identical to compound 1. The connection of glucuronic acid group to the aglycone was also determined in a same manner. Comparing the 13C-NMR data of compound 2 with galangin revealed the downfield shifts of C-6 and C-8 were +1.2 and 1.1, respectively, whereas the upfield shift of C-7 (-3.4 ppm) indicating the
glucuronic acid group was located at C-7. Therefore, compound 2 was identified as GG-2.

**GG-1 and GG-2 inhibit lipid accumulation in HepG2 cells**

To evaluate the effect of GG-1 and GG-2 on lipid metabolism, OA-elicited neutral lipid accumulation in HepG2 cells was used. The intracellular lipid content was determined by oil-red O staining and specific kits for accumulation of lipid, total cholesterol, and triglycerides. Supplementation with OA significantly increased accumulation of lipid in HepG2 cells (Figure 2). Treatment with GG-1 and GG-2 decreased OA-elicited neutral lipid accumulation (Figure 2A) as well as intracellular contents of triglyceride (Figure 2B) and total cholesterol (Figure 2C) in a dose-dependent manner. The inhibitory efficiency of both compounds was higher than that of galangin. The MTT assay showed that the inhibitory effect of GG-1 and GG-2 on lipid metabolism was independent of its cytotoxic effects on HepG2 cells (Figure 3).

**Figure 1:** Chemical structures of galangin, 1 (GG-1), and 2 (GG-2)

**Figure 2:** Effects of GG-1 and GG-2 on lipid accumulation. HepG2 cells were treated with galangin, GG-1, and GG-2 (μM as indicated) or simvastatin (10 μM) in DMEM containing 100 μM of oleic acid or with serum-free DMEM alone (blank) for 24 h. The optical density of 358 nm was obtained after oil-red O staining (A), intracellular levels of triglyceride (B), and total cholesterol (C) were determined. Values are represented as mean±SD. Results are represented in three independent experiments. **P<0.001 vs blank group; *P<0.05, **P<0.01, and ***P<0.001 vs oleic acid group**
Figure 3. Effect of GG-1 and GG-2 on cell viability was determined by MTT assay. The inhibition of cell viability was expressed as a percentage of viable cells in experimental wells than in control wells. Values are represented as mean ± SD. Results are represented in three independent experiments.

Figure 4: Effects of GG-1 and GG-2 on expression of SREBP-1a, SREBP-1c, and SREBP-2, and mRNA levels of FAS, ACC, and HMGR were analyzed using real-time qPCR. The expression level of genes was normalized to β-actin mRNA levels. Values are presented as mean ± SD. Results are represented in three independent experiments; *p < 0.05, **p < 0.01 vs control group.

GG-1 and GG-2 decreased transcription of lipogenesis-related transcription factors and its targeted genes

Real-time qPCR showed that treatment with 10 μM of GG-1 and GG-2 significantly decreased the expression of lipogenic genes such as SREBP-1a, SREBP-1c, and SREBP-2 transcription factors and its downstream genes such as FAS, ACC, and HMGR. GG-1 is more potent in regulation of these lipogenic genes than GG-2 (Figure 4).

DISCUSSION

Herbal medicines have been used in the treatment of obesity for past 100 decades [21,22]. Natural compounds with interesting structures and lipid regulating activities have attracted numerous attentions from chemists and pharmacologists [23]. Statins are the representative compound originated from natural sources with antihyperlipidemic activity [24]. Other compounds such as cordycepin, resveratrol, and berberine are deemed as the effective regulators of lipid metabolism. Galangin has also been proved to have the ability in lowering the lipid levels in liver and blood [10].

However, most natural products are not used as a drug when isolated from natural sources [25]. There are many factors influencing the drug ability. Among all, low biological availability is considered to be the most important factor [26]. Many methods are used to resolve this problem. Finding metabolites from natural products of biological samples have proved to be an effective process in drug discovery [27,28].

Previous studies have found that GG-1 and GG-2 are the main metabolites of blood and urine samples when rats were orally administered with...
galangin. Therefore, GG-1 and GG-2 are considered to be the active in vivo constituents. To verify this hypothesis, the lipid lowering activity of these metabolites has been investigated. The results have demonstrated that GG-1 and GG-2 possess lipid lowering activity. Significantly, these two metabolites showed better hypolipidemic activities than galangin. This may be attributed to the presence of glucuronic acid group in the carbon skeleton. The potential mechanisms have also been investigated and are found to be closely associated with inhibiting key genes or proteins that regulate the biosynthesis of both cholesterol and triglycerides.

CONCLUSION

The findings of this study indicate that both metabolites possess better lipid-lowering activities than galangin. These hypolipidemic activities are closely associated with inhibiting key genes or proteins that regulate the biosynthesis of both cholesterol and triglycerides.

ACKNOWLEDGEMENT

The authors appreciated the financial support provided by the National Natural Science Fund of China (no. 81560721), Hainan Special Plan for the Modernization of Chinese Medicines (no. 2015ZY06), and Hainan Science and Technology Major Project (nos. ZDZX2013008-3 and ZDXM 2015078).

DECLARATIONS

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

REFERENCES

17. Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling.


